Ovarian Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Ovarian Cancer stocks.

Ovarian Cancer Stocks Recent News

Date Stock Title
May 9 MYGN Myriad Genetics First Quarter 2024 Earnings: Beats Expectations
May 8 NKTR Nektar Therapeutics Q1 2024 Earnings Preview
May 8 PSTV Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
May 8 MYGN Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2024 Earnings Call Transcript
May 8 MRUS Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
May 8 MYGN Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1
May 8 MYGN Myriad Genetics surges 17% as Street applauds 2024 guidance, Q1 results
May 8 MYGN Myriad Genetics Inc (MYGN) Q1 2024 Earnings Call Transcript Highlights: Strong Start with ...
May 8 MYGN Myriad Genetics, Inc. (MYGN) Q1 2024 Earnings Call Transcript
May 7 MYGN Myriad (MYGN) Reports Q1 Earnings: What Key Metrics Have to Say
May 7 MYGN Myriad Genetics Reports Q1 2024 Earnings: Revenue Growth Surpasses Estimates Amidst Challenges
May 7 MYGN Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
May 7 MYGN Myriad Genetics GAAP EPS of -$0.29 beats by $0.01, revenue of $202.2M beats by $8.95M
May 7 MYGN Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
May 7 STTK What Makes Shattuck Labs (STTK) a New Buy Stock
May 7 STTK Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect?
May 7 MYGN Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
May 7 MYGN Myriad Genetics (NASDAQ:MYGN) shareholders have endured a 26% loss from investing in the stock five years ago
May 6 MYGN Myriad Genetics Q1 2024 Earnings Preview
May 6 MRUS FDA accepts Merus application for Zeno for lung, pancreatic cancer
Ovarian Cancer

Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body. When this process begins, there may be no or only vague symptoms. Symptoms become more noticeable as the cancer progresses. These symptoms may include bloating, pelvic pain, abdominal swelling, and loss of appetite, among others. Common areas to which the cancer may spread include the lining of the abdomen, lymph nodes, lungs, and liver.The risk of ovarian cancer increases in women who have ovulated more over their lifetime. This includes those who have never had children, those who begin ovulation at a younger age and those who reach menopause at an older age. Other risk factors include hormone therapy after menopause, fertility medication, and obesity. Factors that decrease risk include hormonal birth control, tubal ligation, and breast feeding. About 10% of cases are related to inherited genetic risk; women with mutations in the genes BRCA1 or BRCA2 have about a 50% chance of developing the disease. The most common type of ovarian cancer, comprising more than 95% of cases, is ovarian carcinoma. There are five main subtypes of ovarian carcinoma, of which high-grade serous carcinoma is the most common. These tumors are believed to start in the cells covering the ovaries, though some may form at the Fallopian tubes. Less common types of ovarian cancer include germ cell tumors and sex cord stromal tumors. A diagnosis of ovarian cancer is confirmed through a biopsy of tissue, usually removed during surgery.Screening is not recommended in women who are at average risk, as evidence does not support a reduction in death and the high rate of false positive tests may lead to unneeded surgery, which is accompanied by its own risks. Those at very high risk may have their ovaries removed as a preventive measure. If caught and treated in an early stage, ovarian cancer is often curable. Treatment usually includes some combination of surgery, radiation therapy, and chemotherapy. Outcomes depend on the extent of the disease, the subtype of cancer present, and other medical conditions. The overall five-year survival rate in the United States is 45%. Outcomes are worse in the developing world.In 2012, new cases occurred in 239,000 women. In 2015 it was present in 1.2 million women and resulted in 161,100 deaths worldwide. Among women it is the seventh-most common cancer and the eighth-most common cause of death from cancer. The typical age of diagnosis is 63. Death from ovarian cancer is more common in North America and Europe than in Africa and Asia.

Browse All Tags